204 related articles for article (PubMed ID: 26989130)
1. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
Helfer JL; Wen PY; Blakeley J; Gilbert MR; Armstrong TS
Neuro Oncol; 2016 Mar; 18 Suppl 2(Suppl 2):ii26-ii36. PubMed ID: 26989130
[TBL] [Abstract][Full Text] [Related]
2. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).
Wen PY; Cloughesy TF; Ellingson BM; Reardon DA; Fine HA; Abrey L; Ballman K; Bendszuz M; Buckner J; Chang SM; Prados MD; Pope WB; Gregory Sorensen A; van den Bent M; Yung WK
Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii36-47. PubMed ID: 25313237
[TBL] [Abstract][Full Text] [Related]
3. Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.
Lee EQ; Selig W; Meehan C; Bacha J; Barone A; Bloomquist E; Chang SM; de Groot JF; Galanis E; Hassan I; Kalidas C; Khasraw M; Kvedar JC; Lassman AB; Puduvalli V; Sahebjam S; Schwamm LH; Tamir S; Welch M; Yung WKA; Zadeh G; Arons D; Wen PY
Neuro Oncol; 2021 Aug; 23(8):1252-1260. PubMed ID: 33822177
[TBL] [Abstract][Full Text] [Related]
4. Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.
Fangusaro J; Avery RA; Fisher MJ; Packer RJ; Walsh KS; Schouten-van Meeteren A; Karres D; Bradford D; Bhatnagar V; Singh H; Kluetz PG; Donoghue M; Duke ES
Clin Cancer Res; 2024 Jun; 30(11):2303-2308. PubMed ID: 38358393
[TBL] [Abstract][Full Text] [Related]
5. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
6. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
Bast RC; Thigpen JT; Arbuck SG; Basen-Engquist K; Burke LB; Freedman R; Horning SJ; Ozols R; Rustin GJ; Spriggs D; Wenzel LB; Pazdur R
Gynecol Oncol; 2007 Nov; 107(2):173-6. PubMed ID: 17950384
[TBL] [Abstract][Full Text] [Related]
8. Response Assessment in Neuro-Oncology Clinical Trials.
Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
[TBL] [Abstract][Full Text] [Related]
9. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
Tahara H; Sato M; Thurin M; Wang E; Butterfield LH; Disis ML; Fox BA; Lee PP; Khleif SN; Wigginton JM; Ambs S; Akutsu Y; Chaussabel D; Doki Y; Eremin O; Fridman WH; Hirohashi Y; Imai K; Jacobson J; Jinushi M; Kanamoto A; Kashani-Sabet M; Kato K; Kawakami Y; Kirkwood JM; Kleen TO; Lehmann PV; Liotta L; Lotze MT; Maio M; Malyguine A; Masucci G; Matsubara H; Mayrand-Chung S; Nakamura K; Nishikawa H; Palucka AK; Petricoin EF; Pos Z; Ribas A; Rivoltini L; Sato N; Shiku H; Slingluff CL; Streicher H; Stroncek DF; Takeuchi H; Toyota M; Wada H; Wu X; Wulfkuhle J; Yaguchi T; Zeskind B; Zhao Y; Zocca MB; Marincola FM
J Transl Med; 2009 Jun; 7():45. PubMed ID: 19534815
[TBL] [Abstract][Full Text] [Related]
10. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology.
Cagney DN; Sul J; Huang RY; Ligon KL; Wen PY; Alexander BM
Neuro Oncol; 2018 Aug; 20(9):1162-1172. PubMed ID: 29294069
[TBL] [Abstract][Full Text] [Related]
11. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
[TBL] [Abstract][Full Text] [Related]
12. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.
Huse JT; Wallace M; Aldape KD; Berger MS; Bettegowda C; Brat DJ; Cahill DP; Cloughesy T; Haas-Kogan DA; Marra M; Miller CR; Nelson SJ; Salama SR; Soffietti R; Wen PY; Yip S; Yen K; Costello JF; Chang S
Neuro Oncol; 2014 Jan; 16(2):173-8. PubMed ID: 24305708
[TBL] [Abstract][Full Text] [Related]
13. Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.
Malik SM; Pazdur R; Abrams JS; Socinski MA; Sause WT; Harpole DH; Welch JJ; Korn EL; Ullmann CD; Hirsch FR
J Thorac Oncol; 2014 Oct; 9(10):1443-8. PubMed ID: 25521397
[TBL] [Abstract][Full Text] [Related]
14. Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics.
Rodriguez H; Tezak Z; Mesri M; Carr SA; Liebler DC; Fisher SJ; Tempst P; Hiltke T; Kessler LG; Kinsinger CR; Philip R; Ransohoff DF; Skates SJ; Regnier FE; Anderson NL; Mansfield E;
Clin Chem; 2010 Feb; 56(2):237-43. PubMed ID: 20007859
[TBL] [Abstract][Full Text] [Related]
15. Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.
Armstrong TS; Dirven L; Arons D; Bates A; Chang SM; Coens C; Espinasse C; Gilbert MR; Jenkinson D; Kluetz P; Mendoza T; Rubinstein L; Sul J; Weller M; Wen PY; van den Bent MJ; Taphoorn MJB
Lancet Oncol; 2020 Feb; 21(2):e97-e103. PubMed ID: 32007210
[TBL] [Abstract][Full Text] [Related]
16. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
17. Expanding the Evidence Base in Geriatric Oncology: Action Items From an FDA-ASCO Workshop.
Levit LA; Singh H; Klepin HD; Hurria A
J Natl Cancer Inst; 2018 Nov; 110(11):1163-1170. PubMed ID: 30329076
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.
Blakeley JO; Coons SJ; Corboy JR; Kline Leidy N; Mendoza TR; Wefel JS
Neuro Oncol; 2016 Mar; 18 Suppl 2(Suppl 2):ii13-ii20. PubMed ID: 26989128
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop.
Jarow JP; Lerner SP; Kluetz PG; Liu K; Sridhara R; Bajorin D; Chang S; Dinney CP; Groshen S; Morton RA; O'Donnell M; Quale DZ; Schoenberg M; Seigne J; Vikram B
Urology; 2014 Feb; 83(2):262-4. PubMed ID: 24332121
[TBL] [Abstract][Full Text] [Related]
20. Summary of the FDA virtual public workshop on spinal device clinical review held on September 17, 2021.
Devlin VJ; Jean R; Peat CR; Jiang H; Anderson PA; Benson JC; Brodke DS; Golish SR; Kebaish KM; Larson AN; Serhan H
Spine J; 2022 Sep; 22(9):1423-1433. PubMed ID: 35460900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
